Clinical Trials

Do you have cancer that is treated with something called Bruton's tyrosine kinase inhibitors or BKTi? In this study, researchers want to learn more about Bruton's tyrosine kinase inhibitors, which are often used to treat cancer, affect the heart. You can participate in this study if you are currently receiving or will be receiving Bruton's tyrosine kinase inhibitors. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

Do you have heart disease that requires an ICD to prevent sudden cardiac arrest? This study aims to learn what signs distinguish patients who have a higher risk of an arrhythmia that leads to sudden cardiac arrest. Researchers plan to track patients with a recent ICD replacement for 10 years. To participate in this study, you must be between 18 and 85 years old. This study is located in Washington, D.C.; Baltimore, Maryland; and Richmond, Virginia.

Does your developing baby have a heart defect? Have you had a stillborn baby? This study tests a new technology to measure fetal heart activity and find possible problems early. These problems include fetal arrhythmia and conduction disorders such as Brugada syndrome. To participate in this study, you must be at least 18 years old and pregnant, and have one of five high-risk complications of pregnancy: a fetus with a major congenital heart defect, hydrops, or gastroschisis; a previous unexplained stillbirth; or twins who share a placenta. This study is located in Madison and Milwaukee, Wisconsin.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Do you have a high-risk pregnancy? This study will investigate the use of a non-invasive scan called fetal magnetocardiography to detect potential problems in the fetus in five high-risk pregnancy conditions associated with stillbirth. The scan is normally used to look at fetal heart rhythms. To participate in this study, you must be at least 18 years old and pregnant with one of the following: having a stillbirth in a previous pregnancy, carrying identical twins, or having a fetus that has been diagnosed with major congenital heart disease, fetal hydrops, or fetal gastroschisis. This study takes place in Madison and Milwaukee, Wisconsin.

Are you at least 12 weeks pregnant? This study is recruiting women with healthy pregnancies and women who have experienced an abnormal fetal heart rate or rhythm. Researchers are evaluating fetal magnetocardiography as a new tool to improve the study of fetal heart rate and rhythm. This study is located in Madison, Wisconsin.

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.

This study is evaluating the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB.

Are you a healthy adult between the ages of 18 and 60? For this study, researchers are testing a new medication to treat a lung injury called pulmonary arterial hypertension. First, researchers will test the medication to see how it affects healthy people. To participate, you must be a healthy adult between the ages of 18 and 60. The study will take place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.